{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:55:00Z","timestamp":1792796100273,"version":"4.5.0"},"reference-count":43,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Japan Society for the Promotion of Science","award":["24390403"],"award-info":[{"award-number":["24390403"]}]},{"name":"Japan Society for the Promotion of Science","award":["26670791"],"award-info":[{"award-number":["26670791"]}]},{"name":"Japan Society for the Promotion of Science","award":["15H05008"],"award-info":[{"award-number":["15H05008"]}]},{"name":"Japan Society for the Promotion of Science","award":["18H02905"],"award-info":[{"award-number":["18H02905"]}]},{"name":"Japan Society for the Promotion of Science","award":["22H03176"],"award-info":[{"award-number":["22H03176"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>An effective vaccine against Pseudomonas aeruginosa would benefit people susceptible to severe infection. Vaccination targeting V antigen (PcrV) of the P. aeruginosa type III secretion system is a potential prophylactic strategy for reducing P. aeruginosa-induced acute lung injury and acute mortality. We created a recombinant protein (designated POmT) comprising three antigens: full-length PcrV (PcrV#1-#294), the outer membrane domain (#190-342) of OprF (OprF#190-#342), and a non-catalytic mutant of the carboxyl domain (#406-613) of exotoxin A (mToxA#406-#613(E553\u0394)). In the combination of PcrV and OprF, mToxA, the efficacy of POmT was compared with that of single-antigen vaccines, two-antigen mixed vaccines, and a three-antigen mixed vaccine in a murine model of P. aeruginosa pneumonia. As a result, the 24 h-survival rates were 79%, 78%, 21%, 7%, and 36% in the POmT, PcrV, OprF, mTox, and alum-alone groups, respectively. Significant improvement in acute lung injury and reduction in acute mortality within 24 h after infection was observed in the POmT and PcrV groups than in the other groups. Overall, the POmT vaccine exhibited efficacy comparable to that of the PcrV vaccine. The future goal is to prove the efficacy of the POmT vaccine against various P. aeruginosa strains.<\/jats:p>","DOI":"10.3390\/vaccines11061088","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T01:28:21Z","timestamp":1686533301000},"page":"1088","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Effect of a Novel Trivalent Vaccine Formulation against Acute Lung Injury Caused by Pseudomonas aeruginosa"],"prefix":"10.3390","volume":"11","author":[{"given":"Keita","family":"Inoue","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9478-8764","authenticated-orcid":false,"given":"Mao","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Muranishi","sequence":"additional","affiliation":[{"name":"Department of Emergency and Critical Care Medicine, Faculty of Medicine, Fukuoka University, Fukuoka 814-0180, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Naito","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0387-5406","authenticated-orcid":false,"given":"Kiyoshi","family":"Moriyama","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, School of Medicine, Kyorin University, Mitaka 181-8611, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9558-9011","authenticated-orcid":false,"given":"Teiji","family":"Sawa","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.tim.2011.04.005","article-title":"Pseudomonas aeruginosa: All roads lead to resistance","volume":"19","author":"Breidenstein","year":"2011","journal-title":"Trends Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1164\/rccm.201705-1043SO","article-title":"Mechanisms and targeted therapies for Pseudomonas aeruginosa lung infection","volume":"197","author":"Curran","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Killough, M., Rodgers, A.M., and Ingram, R.J. (2022). Pseudomonas aeruginosa: Recent advances in vaccine development. Vaccines, 10.","DOI":"10.3390\/vaccines10071100"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1586\/14760584.2014.890053","article-title":"Vaccines for Pseudomonas aeruginosa: A long and winding road","volume":"13","author":"Priebe","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"100640","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa\u2014Mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resist. Updat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"fuab026","DOI":"10.1093\/femsre\/fuab026","article-title":"Pseudomonas aeruginosa: A clinical and genomics update","volume":"45","author":"Pelegrin","year":"2021","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/7391","article-title":"Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury","volume":"5","author":"Sawa","year":"1999","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"126719","DOI":"10.1016\/j.micres.2021.126719","article-title":"Type 3 secretion system of Pseudomonas aeruginosa","volume":"246","author":"Horna","year":"2021","journal-title":"Microbiol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/01.CCM.0000145588.79063.07","article-title":"Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU","volume":"32","author":"Pankhaniya","year":"2004","journal-title":"Crit. Care Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.4161\/21645515.2014.971641","article-title":"Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa","volume":"10","author":"Sawa","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1365-2958.2007.05871.x","article-title":"Function and molecular architecture of the Yersinia injectisome tip complex","volume":"65","author":"Broz","year":"2007","journal-title":"Mol. Microbiol."},{"key":"ref_13","first-page":"301","article-title":"The structure of Yersinia pestis V-antigen, an essential virulence factor and mediator of immunity against plague","volume":"12","author":"Derewenda","year":"2004","journal-title":"Structure"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2003.11.029","article-title":"Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections","volume":"22","author":"Baumann","year":"2004","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00050-19","DOI":"10.1128\/JB.00050-19","article-title":"Pushing beyond the envelope: The potential roles of OprF in Pseudomonas aeruginosa biofilm formation and pathogenicity","volume":"201","author":"Cassin","year":"2019","journal-title":"J. Bacteriol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0928-8244(03)00072-5","article-title":"Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients","volume":"37","author":"Mansouri","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_17","first-page":"149","article-title":"Roles of exoenzymes and exotoxin in the pathogenicity of Pseudomonas aeruginosa and the development of a new vaccine","volume":"50","author":"Homma","year":"1980","journal-title":"Jpn. J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJM198006123022410","article-title":"Pseudomonas aeruginosa exotoxin A","volume":"302","author":"Pollack","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S979","DOI":"10.1093\/clinids\/5.Supplement_5.S979","article-title":"The role of exotoxin A in Pseudomonas disease and immunity","volume":"5","author":"Pollack","year":"1983","journal-title":"Rev. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1073\/pnas.81.9.2703","article-title":"Cellular ADP-ribosyltransferase with the same mechanism of action as diphtheria toxin and Pseudomonas toxin A","volume":"81","author":"Lee","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"(2021). Two new pneumococcal vaccines\u2014Prevnar20 and Vaxneuvance. JAMA, 326, 2521\u20132522.","DOI":"10.1001\/jama.2021.22119"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jmb.2013.11.002","article-title":"Structural complementation of the catalytic domain of Pseudomonas exotoxin A","volume":"426","author":"Boland","year":"2014","journal-title":"J. Mol. Biol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1128\/jb.169.11.4967-4971.1987","article-title":"Exotoxin A of Pseudomonas aeruginosa: Substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity","volume":"169","author":"Douglas","year":"1987","journal-title":"J. Bacteriol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1128\/iai.56.12.3095-3098.1988","article-title":"Toxoid of Pseudomonas aeruginosa exotoxin A generated by deletion of an active-site residue","volume":"56","author":"Lukac","year":"1988","journal-title":"Infect. Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/1348-0421.12658","article-title":"The protective effects of nasal PcrV-CpG oligonucleotide vaccination against Pseudomonas aeruginosa pneumonia","volume":"62","author":"Naito","year":"2018","journal-title":"Microbiol. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/infdis\/116.4.481","article-title":"The roles of various fractions of Pseudomonas aeruginosa in its pathogenesis. 3. Identity of the lethal toxins produced in vitro and in vivo","volume":"116","author":"Liu","year":"1966","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/CCM.0000000000001271","article-title":"IV immunoglobulin for acute lung Injury and bacteremia in Pseudomonas aeruginosa pneumonia","volume":"44","author":"Katoh","year":"2016","journal-title":"Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1128\/IAI.66.7.3242-3249.1998","article-title":"In Vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections","volume":"66","author":"Sawa","year":"1998","journal-title":"Infect. Immun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.26565","article-title":"A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF\/I vaccine (IC43) in healthy volunteers","volume":"10","author":"Westritschnig","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13054-020-2792-z","article-title":"Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients-a randomized clinical trial","volume":"24","author":"Adlbrecht","year":"2020","journal-title":"Crit. Care"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13054-017-1601-9","article-title":"A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients","volume":"21","author":"Rello","year":"2017","journal-title":"Crit. Care"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/infdis\/169.5.1159","article-title":"Immunization of noncolonized cystic fibrosis patients against Pseudomonas aeruginosa","volume":"169","author":"Cryz","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/infdis\/174.3.537","article-title":"Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group","volume":"174","author":"Donta","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/01.inf.0000129688.50588.ac","article-title":"Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection","volume":"23","author":"Lang","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1097\/CCM.0b013e31825334f6","article-title":"Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: A randomized, double-blind, placebo-controlled trial","volume":"40","author":"Francois","year":"2012","journal-title":"Crit. Care Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ppul.22890","article-title":"Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection","volume":"49","author":"Milla","year":"2014","journal-title":"Pediatr. Pulmonol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jcf.2017.12.006","article-title":"Study Group. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa","volume":"17","author":"Jain","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2147\/IDR.S244081","article-title":"Protective efficacy of the OprF\/OprI\/PcrV recombinant chimeric protein against Pseudomonas aeruginosa in the burned BALB\/c mouse model","volume":"13","author":"Fakoor","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1038\/s41598-017-04029-5","article-title":"Protective efficacy of the trivalent Pseudomonas aeruginosa vaccine candidate PcrV-OprI-Hcp1 in murine pneumonia and burn models","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1016\/j.vaccine.2006.05.077","article-title":"Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa","volume":"24","author":"Saha","year":"2006","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Jiang, M., Yao, J., and Feng, G. (2014). Protective effect of DNA vaccine encoding Pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096609"},{"key":"ref_42","unstructured":"World Health Organization (2023, May 24). Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations, Available online: https:\/\/www.who.int\/publications\/m\/item\/WHO-TRS-1004-web-annex-9."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"20587384211050199","DOI":"10.1177\/20587384211050199","article-title":"A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies","volume":"35","author":"Nicoletti","year":"2021","journal-title":"Immunopathol. Pharmacol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/6\/1088\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:52:44Z","timestamp":1760125964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/6\/1088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,11]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["vaccines11061088"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11061088","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,11]]}}}